{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:36:11Z","timestamp":1790660171669,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T00:00:00Z","timestamp":1759449600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003252","name":"Lund University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003252","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The vast majority of patients with pancreatic cancer present with unresectable disease and precision medicine is lagging behind. Circulating tumor DNA (ctDNA) has emerged as a promising tool, both as a proxy for tumor burden and for capturing tumor heterogeneity, but optimal gene panels and prognostic cutoffs remain to be determined. Herein, we applied ultra-deep ctDNA sequencing using a customized panel targeting 23 genes and six frequently altered chromosomes on plasma samples obtained before, during and after chemotherapy from 60 patients enrolled in a prospective clinical study. At baseline, positive versus negative ctDNA was not prognostic, neither in the adjuvant nor in the palliative setting, but in palliative patients, an independent prognostic cutoff could be calculated from the absolute number of mutated DNA molecules. Median overall survival was 3.7 months in the ctDNA<jats:sup>high<\/jats:sup> compared to 11.9 months in the ctDNA<jats:sup>low<\/jats:sup> group (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001), and the cutoff remained prognostic at one and three months. Moreover, relevant genetic alterations were highly concordant in ctDNA and paired tumor tissue. These findings demonstrate the potential clinical utility of a customized and focused gene panel for prognostication and target identification over time in patients with newly diagnosed pancreatic cancer, in particular in the palliative setting.<\/jats:p>\n          <jats:p>ClinicalTrials.gov number: NCT03724994.<\/jats:p>","DOI":"10.1038\/s41598-025-22369-5","type":"journal-article","created":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:00:09Z","timestamp":1759482009000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Reliable on-treatment prognostication and target identification with a customized assay for circulating tumor DNA in patients with newly diagnosed pancreatic cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Alexandra","family":"Petersson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofie Olsson","family":"Hau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecka","family":"Bergstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Lindberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Mayrhofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subhayan","family":"Chattopadhyay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob","family":"Eberhard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Heidenblad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Leandersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Gisselsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Jirstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,3]]},"reference":[{"key":"22369_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J. Clin. 70, 7\u201330. https:\/\/doi.org\/10.3322\/caac.21590 (2020).","journal-title":"CA Cancer J. Clin."},{"key":"22369_CR2","doi-asserted-by":"publisher","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","volume":"24","author":"MJ Pishvaian","year":"2018","unstructured":"Pishvaian, M. J. et al. Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative. Clin. Cancer Res. 24, 5018\u20135027. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0531 (2018).","journal-title":"Clin. Cancer Res."},{"key":"22369_CR3","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1016\/S1470-2045(20)30074-7","volume":"21","author":"MJ Pishvaian","year":"2020","unstructured":"Pishvaian, M. J. et al. Overall survival in patients with pancreatic cancer receiving matched therapies following molecular profiling: a retrospective analysis of the know your tumor registry trial. Lancet Oncol. 21, 508\u2013518. https:\/\/doi.org\/10.1016\/S1470-2045(20)30074-7 (2020).","journal-title":"Lancet Oncol."},{"key":"22369_CR4","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1038\/s41591-019-0561-9","volume":"25","author":"AR Parikh","year":"2019","unstructured":"Parikh, A. R. et al. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in Gastrointestinal cancers. Nat. Med. 25, 1415\u20131421. https:\/\/doi.org\/10.1038\/s41591-019-0561-9 (2019).","journal-title":"Nat. Med."},{"key":"22369_CR5","doi-asserted-by":"publisher","first-page":"224ra224","DOI":"10.1126\/scitranslmed.3007094","volume":"6","author":"C Bettegowda","year":"2014","unstructured":"Bettegowda, C. et al. Detection of Circulating tumor DNA in early- and late-stage human malignancies. Sci. Transl Med. 6, 224ra224. https:\/\/doi.org\/10.1126\/scitranslmed.3007094 (2014).","journal-title":"Sci. Transl Med."},{"key":"22369_CR6","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1186\/s13045-019-0824-4","volume":"12","author":"H Patel","year":"2019","unstructured":"Patel, H. et al. Clinical correlates of blood-derived Circulating tumor DNA in pancreatic cancer. J. Hematol. Oncol. 12, 130. https:\/\/doi.org\/10.1186\/s13045-019-0824-4 (2019).","journal-title":"J. Hematol. Oncol."},{"key":"22369_CR7","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41416-021-01624-2","volume":"126","author":"D Pietrasz","year":"2022","unstructured":"Pietrasz, D. et al. Prognostic value of Circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials. Br. J. Cancer. 126, 440\u2013448. https:\/\/doi.org\/10.1038\/s41416-021-01624-2 (2022).","journal-title":"Br. J. Cancer"},{"key":"22369_CR8","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1200\/JCO.1999.17.2.578","volume":"17","author":"A Castells","year":"1999","unstructured":"Castells, A. et al. K-ras mutations in DNA extracted from the plasma of patients with pancreatic carcinoma: diagnostic utility and prognostic significance. J. Clin. Oncol. 17, 578\u2013584. https:\/\/doi.org\/10.1200\/JCO.1999.17.2.578 (1999).","journal-title":"J. Clin. Oncol."},{"key":"22369_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1016\/j.bbcan.2017.08.002","volume":"1868","author":"A Creemers","year":"2017","unstructured":"Creemers, A. et al. Clinical value of ctdna in upper-GI cancers: A systematic review and meta-analysis. Biochim. Biophys. Acta Rev. Cancer. 1868, 394\u2013403. https:\/\/doi.org\/10.1016\/j.bbcan.2017.08.002 (2017).","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"22369_CR10","doi-asserted-by":"publisher","first-page":"2348","DOI":"10.1093\/annonc\/mdy417","volume":"29","author":"S Kruger","year":"2018","unstructured":"Kruger, S. et al. Repeated MutKRAS ctdna measurements represent a novel and promising tool for early response prediction and therapy monitoring in advanced pancreatic cancer. Ann. Oncol. 29, 2348\u20132355. https:\/\/doi.org\/10.1093\/annonc\/mdy417 (2018).","journal-title":"Ann. Oncol."},{"key":"22369_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell, N. et al. Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518, 495\u2013501. https:\/\/doi.org\/10.1038\/nature14169 (2015).","journal-title":"Nature"},{"key":"22369_CR12","doi-asserted-by":"publisher","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones, S. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321, 1801\u20131806. https:\/\/doi.org\/10.1126\/science.1164368 (2008).","journal-title":"Science"},{"key":"22369_CR13","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1038\/s41416-023-02170-9","volume":"128","author":"A Dayimu","year":"2023","unstructured":"Dayimu, A. et al. Clinical and biological markers predictive of treatment response associated with metastatic pancreatic adenocarcinoma. Br. J. Cancer. 128, 1672\u20131680. https:\/\/doi.org\/10.1038\/s41416-023-02170-9 (2023).","journal-title":"Br. J. Cancer"},{"key":"22369_CR14","doi-asserted-by":"publisher","first-page":"e0227366","DOI":"10.1371\/journal.pone.0227366","volume":"14","author":"F Watanabe","year":"2019","unstructured":"Watanabe, F. et al. Longitudinal monitoring of KRAS-mutated Circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer. PLoS One. 14, e0227366. https:\/\/doi.org\/10.1371\/journal.pone.0227366 (2019).","journal-title":"PLoS One"},{"key":"22369_CR15","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1002\/1878-0261.13472","volume":"17","author":"KH Edland","year":"2023","unstructured":"Edland, K. H. et al. Monitoring of Circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging. Mol. Oncol. 17, 1857\u20131870. https:\/\/doi.org\/10.1002\/1878-0261.13472 (2023).","journal-title":"Mol. Oncol."},{"key":"22369_CR16","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1186\/s12885-022-09387-6","volume":"22","author":"L Sivapalan","year":"2022","unstructured":"Sivapalan, L. et al. Longitudinal profiling of Circulating tumour DNA for tracking tumour dynamics in pancreatic cancer. BMC Cancer. 22, 369. https:\/\/doi.org\/10.1186\/s12885-022-09387-6 (2022).","journal-title":"BMC Cancer"},{"key":"22369_CR17","doi-asserted-by":"publisher","first-page":"926260","DOI":"10.3389\/fonc.2022.926260","volume":"12","author":"S Guan","year":"2022","unstructured":"Guan, S. et al. Evaluation of Circulating tumor DNA as a prognostic biomarker for metastatic pancreatic adenocarcinoma. Front. Oncol. 12, 926260. https:\/\/doi.org\/10.3389\/fonc.2022.926260 (2022).","journal-title":"Front. Oncol."},{"key":"22369_CR18","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1158\/1535-7163.MCT-17-1298","volume":"18","author":"T Wei","year":"2019","unstructured":"Wei, T. et al. Monitoring tumor burden in response to FOLFIRINOX chemotherapy via profiling Circulating Cell-Free DNA in pancreatic cancer. Mol. Cancer Ther. 18, 196\u2013203. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-1298 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"22369_CR19","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1186\/s12885-020-06807-3","volume":"20","author":"SO Hau","year":"2020","unstructured":"Hau, S. O. et al. Chemotherapy, host response and molecular dynamics in periampullary cancer: the CHAMP study. BMC Cancer. 20, 308. https:\/\/doi.org\/10.1186\/s12885-020-06807-3 (2020).","journal-title":"BMC Cancer"},{"key":"22369_CR20","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1186\/s12885-023-11562-2","volume":"23","author":"SO Hau","year":"2023","unstructured":"Hau, S. O., Svensson, M., Petersson, A., Eberhard, J. & Jirstrom, K. Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: the CHAMP study. BMC Cancer. 23, 1074. https:\/\/doi.org\/10.1186\/s12885-023-11562-2 (2023).","journal-title":"BMC Cancer"},{"key":"22369_CR21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/1471-2105-15-182","volume":"15","author":"H Jiang","year":"2014","unstructured":"Jiang, H., Lei, R., Ding, S. W. & Zhu, S. Skewer: a fast and accurate adapter trimmer for next-generation sequencing paired-end reads. BMC Bioinform. 15, 182. https:\/\/doi.org\/10.1186\/1471-2105-15-182 (2014).","journal-title":"BMC Bioinform."},{"key":"22369_CR22","unstructured":"Broad Institute. Picard Tools. Broad Institute, Github repository (2018)."},{"key":"22369_CR23","unstructured":"Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv, (2013)."},{"key":"22369_CR24","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1101\/gr.107524.110","volume":"20","author":"A McKenna","year":"2010","unstructured":"McKenna, A. et al. The genome analysis toolkit: a mapreduce framework for analyzing next-generation DNA sequencing data. Genome Res. 20, 1297\u20131303. https:\/\/doi.org\/10.1101\/gr.107524.110 (2010).","journal-title":"Genome Res."},{"key":"22369_CR25","unstructured":"Van der Auwera, G. A. & O\u2019Connor, B. D. Genomics in the Cloud: Using Docker, GATK, and WDL in Terra 1st Edition edn, (O\u2019Reilly Media, (2020)."},{"key":"22369_CR26","doi-asserted-by":"publisher","unstructured":"Benjamin, D. et al. Calling Somatic SNVs and Indels with Mutect2. bioRxiv 861054 (2019). https:\/\/doi.org\/10.1101\/861054","DOI":"10.1101\/861054"},{"key":"22369_CR27","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1093\/bioinformatics\/bts271","volume":"28","author":"CT Saunders","year":"2012","unstructured":"Saunders, C. T. et al. Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 28, 1811\u20131817. https:\/\/doi.org\/10.1093\/bioinformatics\/bts271 (2012).","journal-title":"Bioinformatics"},{"key":"22369_CR28","doi-asserted-by":"publisher","first-page":"e108","DOI":"10.1093\/nar\/gkw227","volume":"44","author":"Z Lai","year":"2016","unstructured":"Lai, Z. et al. VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research. Nucleic Acids Res. 44, e108. https:\/\/doi.org\/10.1093\/nar\/gkw227 (2016).","journal-title":"Nucleic Acids Res."},{"key":"22369_CR29","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1101\/gr.129684.111","volume":"22","author":"DC Koboldt","year":"2012","unstructured":"Koboldt, D. C. et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res. 22, 568\u2013576. https:\/\/doi.org\/10.1101\/gr.129684.111 (2012).","journal-title":"Genome Res."},{"key":"22369_CR30","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1186\/s13059-015-0758-2","volume":"16","author":"LT Fang","year":"2015","unstructured":"Fang, L. T. et al. An ensemble approach to accurately detect somatic mutations using somaticseq. Genome Biol. 16, 197. https:\/\/doi.org\/10.1186\/s13059-015-0758-2 (2015).","journal-title":"Genome Biol."},{"key":"22369_CR31","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/s13059-016-0974-4","volume":"17","author":"W McLaren","year":"2016","unstructured":"McLaren, W. et al. The ensembl variant effect predictor. Genome Biol. 17, 122. https:\/\/doi.org\/10.1186\/s13059-016-0974-4 (2016).","journal-title":"Genome Biol."},{"key":"22369_CR32","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/nbt.1754","volume":"29","author":"JT Robinson","year":"2011","unstructured":"Robinson, J. T. et al. Integrative genomics viewer. Nat. Biotechnol. 29, 24\u201326. https:\/\/doi.org\/10.1038\/nbt.1754 (2011).","journal-title":"Nat. Biotechnol."},{"key":"22369_CR33","doi-asserted-by":"publisher","unstructured":"Poplin, R. et al. Scaling accurate genetic variant discovery to tens of thousands of samples. bioRxiv, 201178 (2018). https:\/\/doi.org\/10.1101\/201178","DOI":"10.1101\/201178"},{"key":"22369_CR34","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1038\/s41586-020-2308-7","volume":"581","author":"KJ Karczewski","year":"2020","unstructured":"Karczewski, K. J. et al. The mutational constraint spectrum quantified from variation in 141,456 humans. Nature 581, 434\u2013443. https:\/\/doi.org\/10.1038\/s41586-020-2308-7 (2020).","journal-title":"Nature"},{"key":"22369_CR35","doi-asserted-by":"publisher","first-page":"D1062","DOI":"10.1093\/nar\/gkx1153","volume":"46","author":"MJ Landrum","year":"2018","unstructured":"Landrum, M. J. et al. ClinVar: improving access to variant interpretations and supporting evidence. Nucleic Acids Res. 46, D1062\u2013D1067. https:\/\/doi.org\/10.1093\/nar\/gkx1153 (2018).","journal-title":"Nucleic Acids Res."},{"key":"22369_CR36","doi-asserted-by":"publisher","first-page":"e1004873","DOI":"10.1371\/journal.pcbi.1004873","volume":"12","author":"E Talevich","year":"2016","unstructured":"Talevich, E., Shain, A. H., Botton, T. & Bastian, B. C. CNVkit: Genome-Wide copy number detection and visualization from targeted DNA sequencing. PLoS Comput. Biol. 12, e1004873. https:\/\/doi.org\/10.1371\/journal.pcbi.1004873 (2016).","journal-title":"PLoS Comput. Biol."},{"key":"22369_CR37","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-21-0986","author":"A Petersson","year":"2022","unstructured":"Petersson, A. et al. Branching copy number evolution and parallel immune profiles across the regional tumor space of resected pancreatic cancer. Mol. Cancer Res. https:\/\/doi.org\/10.1158\/1541-7786.MCR-21-0986 (2022).","journal-title":"Mol. Cancer Res."},{"key":"22369_CR38","doi-asserted-by":"publisher","unstructured":"Rasmussen, M. et al. Allele-specific copy number analysis of tumor samples with aneuploidy and tumor heterogeneity. Genome Biol. 12 (R108). https:\/\/doi.org\/10.1186\/gb-2011-12-10-r108 (2011).","DOI":"10.1186\/gb-2011-12-10-r108"},{"key":"22369_CR39","doi-asserted-by":"publisher","unstructured":"Cancer Genome Atlas Research Network. Electronic address, a. a. d. h. e. & Cancer Genome Atlas Research, N. Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. Cancer Cell 32, 185\u2013203 e113. (2017). https:\/\/doi.org\/10.1016\/j.ccell.2017.07.007","DOI":"10.1016\/j.ccell.2017.07.007"},{"key":"22369_CR40","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1002\/onco.13717","volume":"26","author":"G Botrus","year":"2021","unstructured":"Botrus, G. et al. Circulating tumor DNA-Based testing and actionable findings in patients with advanced and metastatic pancreatic adenocarcinoma. Oncologist 26, 569\u2013578. https:\/\/doi.org\/10.1002\/onco.13717 (2021).","journal-title":"Oncologist"},{"key":"22369_CR41","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1038\/nature19823","volume":"538","author":"F Notta","year":"2016","unstructured":"Notta, F. et al. A renewed model of pancreatic cancer evolution based on genomic rearrangement patterns. Nature 538, 378\u2013382. https:\/\/doi.org\/10.1038\/nature19823 (2016).","journal-title":"Nature"},{"key":"22369_CR42","unstructured":"Garrison, E. & Marth, G. Haplotype-based variant detection from short-read sequencing. arXiv:1207.3907  (2012)."},{"key":"22369_CR43","doi-asserted-by":"publisher","unstructured":"Danecek, P. et al. Twelve years of samtools and BCFtools. GigaScience 10 https:\/\/doi.org\/10.1093\/gigascience\/giab008 (2021).","DOI":"10.1093\/gigascience\/giab008"},{"key":"22369_CR44","doi-asserted-by":"publisher","unstructured":"Mayrhofer, M. et al. Sensitive detection of copy number alterations in samples with low circulating tumor DNA fraction. medRxiv, 2024.2005.2004.24306860 (2024). https:\/\/doi.org\/10.1101\/2024.05.04.24306860","DOI":"10.1101\/2024.05.04.24306860"},{"key":"22369_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41523-024-00642-6","volume":"10","author":"A Alba-Bernal","year":"2024","unstructured":"Alba-Bernal, A. et al. Increased blood draws for ultrasensitive ctdna and CTCs detection in early breast cancer patients. NPJ Breast Cancer. 10, 36. https:\/\/doi.org\/10.1038\/s41523-024-00642-6 (2024).","journal-title":"NPJ Breast Cancer"},{"key":"22369_CR46","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. Fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890. https:\/\/doi.org\/10.1093\/bioinformatics\/bty560 (2018).","journal-title":"Bioinformatics"},{"key":"22369_CR47","doi-asserted-by":"publisher","unstructured":"Bourbon, E., Alcazer, V., Cheli, E., Huet, S. & Sujobert, P. How to obtain a high quality ctdna in lymphoma patients: preanalytical tips and tricks. Pharmaceuticals (Basel). 14. https:\/\/doi.org\/10.3390\/ph14070617 (2021).","DOI":"10.3390\/ph14070617"},{"key":"22369_CR48","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1093\/annonc\/mdx212","volume":"28","author":"L Cabel","year":"2017","unstructured":"Cabel, L. et al. Circulating tumor DNA changes for early monitoring of anti-PD1 immunotherapy: a proof-of-concept study. Ann. Oncol. 28, 1996\u20132001. https:\/\/doi.org\/10.1093\/annonc\/mdx212 (2017).","journal-title":"Ann. Oncol."},{"key":"22369_CR49","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1093\/oncolo\/oyae155","volume":"29","author":"GP Botta","year":"2024","unstructured":"Botta, G. P. et al. Association of personalized and tumor-informed ctdna with patient survival outcomes in pancreatic adenocarcinoma. Oncologist 29, 859\u2013869. https:\/\/doi.org\/10.1093\/oncolo\/oyae155 (2024).","journal-title":"Oncologist"},{"key":"22369_CR50","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1001\/jamaoncol.2024.1575","volume":"10","author":"M Cecchini","year":"2024","unstructured":"Cecchini, M. et al. Perioperative modified FOLFIRINOX for resectable pancreatic cancer: A nonrandomized controlled trial. JAMA Oncol. 10, 1027\u20131035. https:\/\/doi.org\/10.1001\/jamaoncol.2024.1575 (2024).","journal-title":"JAMA Oncol."},{"key":"22369_CR51","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nrc.2017.7","volume":"17","author":"JCM Wan","year":"2017","unstructured":"Wan, J. C. M. et al. Liquid biopsies come of age: towards implementation of Circulating tumour DNA. Nat. Rev. Cancer. 17, 223\u2013238. https:\/\/doi.org\/10.1038\/nrc.2017.7 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"22369_CR52","doi-asserted-by":"publisher","first-page":"e0235623","DOI":"10.1371\/journal.pone.0235623","volume":"15","author":"Y Uesato","year":"2020","unstructured":"Uesato, Y. et al. Evaluation of Circulating tumor DNA as a biomarker in pancreatic cancer with liver metastasis. PLoS One. 15, e0235623. https:\/\/doi.org\/10.1371\/journal.pone.0235623 (2020).","journal-title":"PLoS One"},{"key":"22369_CR53","doi-asserted-by":"publisher","first-page":"7048","DOI":"10.1038\/s41598-020-64068-3","volume":"10","author":"H Wang","year":"2020","unstructured":"Wang, H. et al. Survival of pancreatic cancer patients is negatively correlated with age at diagnosis: a population-based retrospective study. Sci. Rep. 10, 7048. https:\/\/doi.org\/10.1038\/s41598-020-64068-3 (2020).","journal-title":"Sci. Rep."},{"key":"22369_CR54","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/978-3-319-42044-8_3","volume":"924","author":"E Takai","year":"2016","unstructured":"Takai, E. et al. Clinical utility of Circulating tumor DNA for molecular assessment and precision medicine in pancreatic cancer. Adv. Exp. Med. Biol. 924, 13\u201317. https:\/\/doi.org\/10.1007\/978-3-319-42044-8_3 (2016).","journal-title":"Adv. Exp. Med. Biol."},{"key":"22369_CR55","doi-asserted-by":"publisher","first-page":"101539","DOI":"10.1016\/j.esmoop.2023.101539","volume":"8","author":"TM Reissig","year":"2023","unstructured":"Reissig, T. M. et al. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer. ESMO Open. 8, 101539. https:\/\/doi.org\/10.1016\/j.esmoop.2023.101539 (2023).","journal-title":"ESMO Open."},{"key":"22369_CR56","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1158\/2159-8290.CD-15-0274","volume":"5","author":"OA Zill","year":"2015","unstructured":"Zill, O. A. et al. Cell-Free DNA Next-Generation sequencing in pancreatobiliary carcinomas. Cancer Discov. 5, 1040\u20131048. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0274 (2015).","journal-title":"Cancer Discov"},{"key":"22369_CR57","doi-asserted-by":"publisher","first-page":"4875","DOI":"10.1158\/0008-5472.CAN-12-2217","volume":"72","author":"C Swanton","year":"2012","unstructured":"Swanton, C. Intratumor heterogeneity: evolution through space and time. Cancer Res. 72, 4875\u20134882. https:\/\/doi.org\/10.1158\/0008-5472.CAN-12-2217 (2012).","journal-title":"Cancer Res."},{"key":"22369_CR58","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s43018-019-0002-1","volume":"1","author":"CA Iacobuzio-Donahue","year":"2020","unstructured":"Iacobuzio-Donahue, C. A., Litchfield, K. & Swanton, C. Intratumor heterogeneity reflects clinical disease course. Nat. Cancer. 1, 3\u20136. https:\/\/doi.org\/10.1038\/s43018-019-0002-1 (2020).","journal-title":"Nat. Cancer"},{"key":"22369_CR59","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1158\/1078-0432.CCR-22-3526","volume":"29","author":"M Lapin","year":"2023","unstructured":"Lapin, M. et al. Comprehensive ctdna measurements improve prediction of clinical outcomes and enable dynamic tracking of disease progression in advanced pancreatic cancer. Clin. Cancer Res. 29, 1267\u20131278. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3526 (2023).","journal-title":"Clin. Cancer Res."},{"key":"22369_CR60","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1002\/1878-0261.12757","volume":"14","author":"T Wei","year":"2020","unstructured":"Wei, T. et al. Genome-wide profiling of Circulating tumor DNA depicts landscape of copy number alterations in pancreatic cancer with liver metastasis. Mol. Oncol. 14, 1966\u20131977. https:\/\/doi.org\/10.1002\/1878-0261.12757 (2020).","journal-title":"Mol. Oncol."},{"key":"22369_CR61","doi-asserted-by":"publisher","first-page":"11610","DOI":"10.1038\/s41598-019-47489-7","volume":"9","author":"S Mohan","year":"2019","unstructured":"Mohan, S. et al. Analysis of Circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in pancreatic cancer. Sci. Rep. 9, 11610. https:\/\/doi.org\/10.1038\/s41598-019-47489-7 (2019).","journal-title":"Sci. Rep."},{"key":"22369_CR62","doi-asserted-by":"publisher","first-page":"172","DOI":"10.3892\/mco.2021.2334","volume":"15","author":"F Pittella-Silva","year":"2021","unstructured":"Pittella-Silva, F., Kimura, Y., Low, S. K., Nakamura, Y. & Motoya, M. Amplification of mutant KRAS(G12D) in a patient with advanced metastatic pancreatic adenocarcinoma detected by liquid biopsy: A case report. Mol. Clin. Oncol. 15, 172. https:\/\/doi.org\/10.3892\/mco.2021.2334 (2021).","journal-title":"Mol. Clin. Oncol."},{"key":"22369_CR63","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","volume":"5","author":"MM Oken","year":"1982","unstructured":"Oken, M. M. et al. Toxicity and response criteria of the Eastern cooperative oncology group. Am. J. Clin. Oncol. 5, 649\u2013655 (1982).","journal-title":"Am. J. Clin. Oncol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22369-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22369-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:00:12Z","timestamp":1759482012000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-22369-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,3]]},"references-count":63,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["22369"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-22369-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,3]]},"assertion":[{"value":"22 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Karin Leandersson has received honoraria from Cantargia AB outside this work. The other authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"34481"}}